Greenwich LifeSciences (GLSI) Expected to Post Quarterly Earnings on Thursday

Greenwich LifeSciences (NASDAQ:GLSI) is expected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.33) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 8:00 AM ET.

Greenwich LifeSciences Trading Up 0.3%

Shares of NASDAQ GLSI opened at $14.39 on Thursday. The stock has a 50 day moving average of $19.95 and a 200-day moving average of $23.72. The company has a market capitalization of $211.25 million, a P/E ratio of -9.17 and a beta of 1.46. Greenwich LifeSciences has a 12 month low of $7.78 and a 12 month high of $34.10.

Insider Activity

In related news, CEO Snehal Patel purchased 2,500 shares of the firm’s stock in a transaction that occurred on Thursday, July 23rd. The shares were bought at an average price of $13.14 per share, for a total transaction of $32,850.00. Following the completion of the transaction, the chief executive officer owned 5,606,602 shares of the company’s stock, valued at approximately $73,670,750.28. This trade represents a 0.04% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Over the last quarter, insiders acquired 5,800 shares of company stock worth $76,618. Corporate insiders own 51.47% of the company’s stock.

Institutional Investors Weigh In On Greenwich LifeSciences

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Greenwich LifeSciences by 22.3% in the 4th quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after buying an additional 1,322 shares during the period. Strs Ohio acquired a new position in shares of Greenwich LifeSciences in the 1st quarter valued at approximately $177,000. Rhumbline Advisers lifted its holdings in shares of Greenwich LifeSciences by 48.7% during the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock worth $92,000 after acquiring an additional 3,168 shares during the period. Geode Capital Management LLC boosted its position in shares of Greenwich LifeSciences by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 138,982 shares of the company’s stock worth $1,261,000 after acquiring an additional 1,972 shares in the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Greenwich LifeSciences during the 2nd quarter worth approximately $509,000. Institutional investors own 4.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on GLSI shares. HC Wainwright lifted their price objective on shares of Greenwich LifeSciences from $50.00 to $69.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Friday, May 15th. Finally, Wall Street Zen downgraded shares of Greenwich LifeSciences from a “hold” rating to a “sell” rating in a research report on Saturday, June 6th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $57.00.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.